N4 Pharma PLC Notice of AGM & Posting Annual Report and Accounts (2412Q)
February 25 2021 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 2412Q
N4 Pharma PLC
25 February 2021
25 February 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Notice of Annual General Meeting
and
Posting of Annual Report and Accounts
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that the Company's audited accounts for the
year ended 31 December 2020, together with the notice of Annual
General Meeting ("AGM"), are now available on the Company's website
www.n4pharma.com and will be posted to shareholders today.
The AGM will be held at 10.00am on 24 March 2021. In line with
current Covid-19 restrictions and in line with the Company's
Articles of Association, this year's AGM will be a virtual meeting,
full details of which are contained in the notice convening the
AGM.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker/Zoe Alexander
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSSESFILEFSESE
(END) Dow Jones Newswires
February 25, 2021 02:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024